Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Oct 26;10(11):1797.
doi: 10.3390/vaccines10111797.

Evaluation of the Efficacy of COVID-19 Booster Vaccinations in Healthcare Personnel

Chung-Jong Kim  1   2   3 , Ji-Yun Bae  2   4   5 , Kang-Il Jun  1   3 , Jihee Kim  3 , Hee-Jung Son  5 , Hae-Sun Chung  2   6 , Soo-Kyung Kim  7 , Soohyun Kim  8 , Dohsik Minn  8 , Hee-Jung Choi  2   4   5
Affiliations

Evaluation of the Efficacy of COVID-19 Booster Vaccinations in Healthcare Personnel

Chung-Jong Kim et al. Vaccines (Basel). .

Abstract

This study aimed to investigate the efficacy of different COVID-19 booster vaccines by measuring the serum antibody titer. SARS-CoV-2 anti-nucleocapsid protein antibody (N-Ab), anti-spike protein antibody (S-Ab), and neutralizing antibody (Neut.Ab) were measured before and 4-6 weeks after booster vaccinations in healthcare personnel with a previous vaccination within 3-6 months. Personnel who previously received two doses of ChAdOx1 vaccine or two doses of BNT162b2 vaccine received the BNT162b2 vaccine (AAP and PPP groups, respectively). Personnel who previously received two doses of mRNA-1273 received the same vaccine as a booster dose (MMM group). Of the 917 participants, the AAP, MMM, and PPP groups comprised 837 (91.3%), 27 (2.9%), and 53 (5.8%) participants, respectively. The pre-booster S-Ab and Neut.Ab titer were significantly lower in the AAP group. After the booster vaccination, all participants were positive for S-Ab and Neut.Ab; furthermore, the S-Ab and Neut.Ab titer significantly increased in all three groups, although the post-booster S-Ab was lower in the AAP group than in the other groups. The post-booster Neut.Ab titer showed no significant difference among the groups. Our study's results suggest that booster vaccination, after two prior vaccinations, shows a significant effect regardless of the type of vaccine administered.

Keywords: COVID-19 vaccine booster shot; COVID-19 vaccines; SARS-CoV-2; antibodies.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
S-Ab (a) and Neut.Ab (b) titer before and after the COVID-19 booster vaccination in different vaccination groups.
Figure 1
Figure 1
S-Ab (a) and Neut.Ab (b) titer before and after the COVID-19 booster vaccination in different vaccination groups.
Figure 2
Figure 2
S-Ab (a) and Neut.Ab (b) titer before and after the COVID-19 booster vaccination depending on the age group.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Petersen E., Koopmans M., Go U., Hamer D.H., Petrosillo N., Castelli F., Storgaard M., Al Khalili S., Simonsen L. Comparing SARS-CoV-2 with SARS-CoV and influenza pandemics. Lancet Infect. Dis. 2020;20:e238–e244. doi: 10.1016/S1473-3099(20)30484-9. - DOI - PMC - PubMed
    1. Buera F.J., Fattal-Jaef R.N., Hopenhayn H., Neumeyer P.A., Shin Y. The Economic Ripple Effects of COVID-19. National Bureau of Economic Research; Cambridge, MA, USA: 2021.
    1. Iacus S.M., Natale F., Santamaria C., Spyratos S., Vespe M. Estimating and projecting air passenger traffic during the COVID-19 coronavirus outbreak and its socio-economic impact. Saf. Sci. 2020;129:104791. doi: 10.1016/j.ssci.2020.104791. - DOI - PMC - PubMed
    1. Salasc F., Lahlali T., Laurent E., Rosa-Calatrava M., Pizzorno A. Treatments for COVID-19: Lessons from 2020 and new therapeutic options. Curr. Opin. Pharmacol. 2022;62:43–59. doi: 10.1016/j.coph.2021.11.002. - DOI - PMC - PubMed
    1. Okoli G.N., Rabbani R., Al-Juboori A., Copstein L., Askin N., Abou-Setta A.M. Antiviral drugs for coronavirus disease 2019 (COVID-19): A systematic review with network meta-analysis. Expert Rev. Anti-Infect. Ther. 2022;20:267–278. doi: 10.1080/14787210.2021.1961579. - DOI - PMC - PubMed

LinkOut - more resources